| Age at diagnosis (years) |
54.7 (23.9) |
83 |
50.0 (22.0) |
26 |
0.235 |
| Gender (male/female) |
28 / 55 |
|
11 / 15 |
|
0.285 |
| AIH scorea
|
14.0 (4.0) |
83 |
12.0 (4.0) |
26 |
0.229 |
| follow up time (months) |
53.9 (54.3) |
83 |
81.3 (66.8) |
26 |
0.005 |
| time to biochemical remission* (months) |
6.5 (10.0) |
78 |
|
|
|
| Autoantibodies |
|
|
|
|
|
| ANA |
72 / 83 |
|
21 / 26 |
|
0.321 |
| SMA |
61 / 82 |
|
18 / 24 |
|
0.590 |
| SLA |
5 / 76 |
|
1 / 22 |
|
1.000 |
| pANCA |
21 / 24 |
|
9 / 10 |
|
0.666 |
| Laboratory test |
|
|
|
|
|
| IgG (times ULN) |
1.35 (0.69) |
83 |
1.56 (0.77) |
26 |
0.034 |
| Alanine aminotransferase (times ULN) |
21.3 (27.3) |
83 |
16.4 (21.9) |
26 |
0.184 |
| Aspartate aminotransferase (times ULN) |
20.3 (28.7) |
83 |
18.3 (19.0) |
25 |
0.054 |
| Glutamate dehydrogenase (times ULN) |
5.0 (5.0) |
59 |
3.8 (3.0) |
21 |
0.118 |
| Gamma-glutamyl transferase (times ULN) |
4.4 (6.3) |
83 |
4.8 (5.9) |
24 |
0.638 |
| Alkaline phosphatase (times ULN) |
1.3 (1.0) |
82 |
1.4 (0.8) |
26 |
0.301 |
| Bilirubin (times ULN) |
4.3 (13.6) |
80 |
3.1 (9.8) |
26 |
0.368 |
| Prothrombin time (%) |
70.0 (30.0) |
82 |
76.5 (34.5) |
22 |
0.243 |
| Albumin (g/l) |
35.0 (8.0) |
67 |
35.5 (7.8) |
18 |
0.690 |
| Iron homeostasis |
|
|
|
|
|
| Hemoglobin (g/dl) |
13.5 (1.9) |
83 |
13.2 (1.5) |
26 |
0.127 |
| Serum iron (μmol/l) |
1.26 (0.79) |
67 |
0.81 (0.45) |
19 |
0.003 |
| Transferrinsaturation (%) |
50.5 (48.0) |
58 |
35.0 (23.0) |
17 |
0.081 |
| Iron binding capacity of transferrin (μmol/l) |
60.0 (24.0) |
60 |
58.0 (15.0) |
17 |
0.645 |
| Ferritin (times ULN) |
2.59 (6.16) |
83 |
1.23 (1.85) |
26 |
0.035 |
| Soluble transferrin receptor (nM) |
14.5 (6.8) |
18 |
13.8 (12.2) |
5 |
0.881 |
| Ferritinindex (sTfR / logFerritin) |
0.40 (0.21) |
17 |
0.45 (0.81) |
5 |
0.649 |
| Hepcidin (ng/ml) |
1.8 (4.3) |
21 |
5.2 (6.8) |
8 |
0.114 |
| Acute phase proteins |
|
|
|
|
|
| C-reactive protein (mg/l) |
7.5 (12.0) |
80 |
7.0 (8.0) |
23 |
0.921 |
| TNF alpha (ng/ml) |
23.4 (32.7) |
53 |
35.8 (20.2) |
14 |
0.194 |
| IL6 (ng/ml) |
19.1 (19.5) |
52 |
21.0 (55.9) |
14 |
0.461 |
| Histology |
|
|
|
|
|
| mHAI |
9.0 (4.0) |
58 |
9.0 (3.0) |
14 |
0.976 |
| Ishak A |
3.0 (1.0) |
58 |
3.5 (1.0) |
14 |
0.684 |
| Ishak B |
0.0 (2.0) |
58 |
0.0 (1.0) |
14 |
0.638 |
| Ishak C |
2.0 (1.0) |
58 |
2.0 (2.0) |
14 |
0.739 |
| Ishak D |
3.0 (1.0) |
58 |
3.0 (2.0) |
14 |
0.410 |
| Fibrosis |
3.0 (4.0) |
63 |
3.0 (4.0) |
17 |
0.643 |
|
Hepatic iron score**
|
|
|
|
|
|
| total |
0.0 (4.0) |
47 |
0.0 (3.0) |
10 |
0.598 |
| hepatocytic |
0.0 (0.0) |
47 |
0.0 (0.0) |
10 |
0.444 |
| sinusoidal |
0.0 (1.0) |
47 |
0.0 (0.0) |
10 |
0.217 |
| portal |
0.0 (0.0) |
47 |
0.0 (0.0) |
10 |
0.426 |
| Induktion therapy |
|
|
|
|
|
| Prednisolone/Budesonide |
74 / 5 |
|
20 / 5 |
|
0.058 |
| Prednisolone dose (mg/day) |
60.0 (10.0) |
74 |
60.0 (10.0) |
20 |
0.952 |
| Budesonide dose (mg/day) |
9.0 (-) |
5 |
9.0 (-) |
5 |
1.000 |
| Azathioprine |
52 / 83 |
|
16 / 10 |
|
0.548 |
| Azathioprine dose (mg/day) |
50.0 (50.0) |
27 |
100.0 (62.5) |
9 |
0.079 |
